Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Net Income | -839.36% | -750.08% | -119.42% | -115.18% | -104.48% |
| Total Depreciation and Amortization | 13.57% | 14.78% | -8.03% | 16.94% | -1.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.12% | 18.47% | 3,138.86% | 11,330.23% | 26,950.38% |
| Change in Net Operating Assets | -589.69% | 146.43% | -169.54% | 321.87% | 132.55% |
| Cash from Operations | -21.81% | 0.42% | -5.86% | 5.02% | 10.22% |
| Capital Expenditure | -1.21% | 5.93% | 12.67% | 20.52% | 26.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -7,291.97% | -- | 100.00% | 100.00% | 96.21% |
| Divestitures | 244.57% | -- | -- | -- | -- |
| Other Investing Activities | -207.72% | -14.61% | 80.35% | 121.43% | 92.01% |
| Cash from Investing | -179.18% | 14.59% | 52.71% | 61.29% | 57.37% |
| Total Debt Issued | 43.99% | 13.49% | -17.21% | 5.50% | 35.30% |
| Total Debt Repaid | -15.17% | 9.67% | 19.51% | 8.40% | -36.87% |
| Issuance of Common Stock | -18.37% | -97.01% | -97.35% | -95.19% | -93.28% |
| Repurchase of Common Stock | 53.38% | -202.64% | -202.63% | -2,401.87% | -3,094.12% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 37.32% | -26.57% | -33.21% | -90.40% | -442.10% |
| Cash from Financing | 87.60% | 2.58% | -59.54% | -100.67% | -629.96% |
| Foreign Exchange rate Adjustments | 487.52% | 207.75% | -83.32% | 334.72% | -89.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.61% | 113.21% | -105.26% | 113.45% | -182.38% |